Aurobindo Pharma said that it would make and sell US-based COVAXX’s COVID-19 vaccine candidate for supply in India and to the United Nations Children’s Fund (UNICEF) under a licensing deal.
The Indian drugmaker also has non-exclusive rights to sell the shot — which is currently undergoing an early-stage trial — in certain other emerging markets, the Hyderabad-based company said in an exchange filing.
COVAXX, a unit of privately-owned United Biomedical, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the United States.
The companies said the shot uses normal refrigeration as opposed to the freezing temperatures required for some vaccines, seen as beneficial for developing countries.
Aurobindo said it could currently produce 220 million doses, but is ramping up its facilities to reach a capacity of nearly 480 million by June 2021.
Its licensing deal comes as COVID-19 infections in India continue to rise after crossing 10 million last week. It’s the second worst-hit nation by the pandemic after the United States.
Commenting on the development, N Govindarajan, Managing Director, Aurobindo Pharma, said, “We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the COVID-19 pandemic. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.”
Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX’s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. Aurobindo will manufacture the finished doses at its facilities in Hyderabad. Aurobindo has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June 2021.
“COVAXX is committed to providing an equitable distribution of UB-612 by prioritising emerging markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO, COVAXX. “During this global health crisis response, we must establish partners with the strongest capabilities, like Aurobindo, to prioritise the development and the delivery of our vaccine. As one of the leading industry players with a strong track record of execution and investment in vaccines, Aurobindo Pharma is the ideal partner to advance UB-612 in India and other emerging nations and to support our mission of democratising health worldwide.”
Last month, COVAXX said it had received purchase commitments totaling $2.8 billion to deliver more than 140 million doses of its potential COVID-19 vaccine to developing countries, including Brazil, Peru and Ecuador.
thank you